Vote math updated for Drugs Made In America (DMAA) in proxy amendment

Rhea-AI Filing Summary

Drugs Made In America Acquisition Corp. filed Amendment No. 1 to its definitive proxy statement to update voting thresholds and share counts tied to an Extraordinary General Meeting. The amendment states 33,517,143 Ordinary Shares outstanding as of the Record Date and elsewhere lists 33,717,143 Ordinary Shares as of the Record Date. It specifies that, assuming all Ordinary Shares are present, the Company will need 11,827,619 and alternatively 11,760,953 Public Shares to approve the Extension Proposal, and 6,241,429 and alternatively 6,141,429 Public Shares to approve the Adjournment Proposal. The Amendment replaces Article 48.7 and is dated April 16, 2026.

Insights

Corporate Governance Analyst

The amendment clarifies vote math and corrects charter language ahead of the Extraordinary General Meeting.

The filing supplies explicit vote thresholds tied to total Ordinary Shares present and updates Article 48.7. Multiple close but differing outstanding‑share figures appear in the text; these should be reconciled in final materials to avoid shareholder confusion.

Watch for subsequent clarification filings or meeting materials that confirm the definitive shares outstanding and the exact vote counts required for each proposal.

Key Figures

Ordinary Shares outstanding (figure 1): 33,517,143 shares Ordinary Shares outstanding (figure 2): 33,717,143 shares Public Shares needed for Extension (figure 1): 11,827,619 shares +4 more

7 metrics

Ordinary Shares outstanding (figure 1) 33,517,143 shares as of the Record Date

Ordinary Shares outstanding (figure 2) 33,717,143 shares as of the Record Date (alternate figure appearing in the filing)

Public Shares needed for Extension (figure 1) 11,827,619 shares assuming all Ordinary Shares present at the Extraordinary General Meeting

Public Shares needed for Extension (figure 2) 11,760,953 shares alternate figure stated in the filing

Public Shares needed for Adjournment (figure 1) 6,241,429 shares assuming all Ordinary Shares present at the Extraordinary General Meeting

Public Shares needed for Adjournment (figure 2) 6,141,429 shares alternate figure stated in the filing

Amendment date April 16, 2026 date of Amendment No. 1

Key Terms

Extraordinary General Meeting, Private Placement Units, Founder Shares, Record Date, +1 more

5 terms

Extraordinary General Meeting regulatory

"if all outstanding Ordinary Shares are present at the Extraordinary General Meeting"

Private Placement Units financial

"in addition to the Founder Shares and shares included in the Private Placement Units"

Founder Shares financial

"in addition to the Founder Shares and the shares included in the Private Placement Units"

Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.

Record Date regulatory

"On the Record Date, there were 33,517,14333,717,143 Ordinary Shares"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

Adjournment Proposal regulatory

"the Company will need 6,241,4296,141,429 of the outstanding Public Shares to vote in favor of the Adjournment Proposal"

An adjournment proposal is a formal request made at a shareholder or board meeting to pause the meeting and reconvene at a later date or time. It matters to investors because it postpones votes and decisions, giving parties extra time to gather information, solicit support, negotiate alternatives or introduce new options — like hitting pause on a group decision to wait for more facts, which can alter outcomes and market reactions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. 1)

Filed by the Registrant	☒
Filed by a Party other than the Registrant	☐

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material Pursuant to Section240.14a-12

DRUGS MADE IN AMERICA ACQUISITION CORP.
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

EXPLANATORY NOTE

Drugs Made in America Acquisition Corp. (the “Company”) is filing this amendment (the “Amendment”) to its definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 14, 2026 (the “Proxy Statement”) to provide the following updates:

The notice:

As of the date of this Proxy Statement, the Company has 33,517,14333,717,143 Ordinary Shares outstanding. Accordingly, if all outstanding Ordinary Shares are present at the Extraordinary General Meeting, then in addition to the Founder Shares and shares included in the Private Placement Units (as defined below), the Company will need 11,827,61911,760,953 Public Shares to vote in favor of the Extension Proposal to approve such proposal.

Assuming all outstanding Ordinary Shares are present at the Extraordinary General Meeting, then in addition to the Founder Shares and the shares included in the Private Placement Units, the Company will need 6,241,4296,141,429 of the outstanding Public Shares to vote in favor of the Adjournment Proposal to approve such proposal.

Page 2:

On the Record Date, there were 33,517,14333,717,143 Ordinary Shares, $0.0001 par value (the “Ordinary Shares”), issued and outstanding.

Page 19:

At the close of business on the Record Date, there were 33,517,14333,717,143 Ordinary Shares, par value $0.0001 per share, issued and outstanding, each of which entitles its holder to cast one vote on the proposal.

Page 21:

(2) Drugs Made In America Acquisition LLC, our sponsor, is the record holder of the shares reported herein. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.

Annex A:

Article 48.7 shall be deleted in its entirety and replaced by the following:

48.7 In the event that the Company does not consummate a Business Combination by April 29, 2027 by depositing $0.02the lesser of $300,000 or $0.04 per non-redeemed Public Share into the Trust Account each month until April 29, 2027, or such later time as the Members may approve in accordance with the Articles, the Company shall:

Terms used in this Amendment that are not defined in this Amendment have the meanings given to them in the Proxy Statement.

The date of this Amendment is April 16, 2026.

FAQ

How many Ordinary Shares does DMAA report outstanding as of the Record Date?

The amendment lists 33,517,143 Ordinary Shares as of the Record Date. Elsewhere the filing also lists 33,717,143 Ordinary Shares as of the Record Date, showing two close figures in the text.

What vote is required to approve the Extension Proposal in the DMAA proxy amendment?

Assuming all Ordinary Shares are present, the Company states it needs 11,827,619 Public Shares to vote in favor. The filing also lists an alternate figure of 11,760,953 Public Shares in another location.

How many Public Shares are required for the Adjournment Proposal?

The amendment states the Company needs 6,241,429 Public Shares to approve the Adjournment Proposal; an alternate figure of 6,141,429 Public Shares also appears in the filing.

Who holds the record shares for DMAA's sponsor disclosure?

The filing identifies Drugs Made In America Acquisition LLC as the record holder and names Lynn Stockwell as managing member with voting and dispositive power, while disclaiming beneficial ownership except for pecuniary interest.

When was Amendment No. 1 to the proxy statement dated?

The amendment is dated April 16, 2026 and replaces Article 48.7 in the proxy materials, per the filing text.